{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:39Z","timestamp":1793042679599,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.canlet.2024.217100","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:16:48Z","timestamp":1720045008000},"page":"217100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study"],"prefix":"10.1016","volume":"598","author":[{"given":"Kevin Sheng-Kai","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7910-2338","authenticated-orcid":false,"given":"Cho-Hung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-2497","authenticated-orcid":false,"given":"Yen","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hsien","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8759-3093","authenticated-orcid":false,"given":"Yuan Ping","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ming","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-6161","authenticated-orcid":false,"given":"Cho-Han","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.canlet.2024.217100_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.canlet.2024.217100_bib2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.canlet.2024.217100_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.217100_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"26","key":"10.1016\/j.canlet.2024.217100_bib5","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.canlet.2024.217100_bib6","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canlet.2024.217100_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217100_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030792","article-title":"Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases","volume":"14","author":"Yura","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.canlet.2024.217100_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"24","key":"10.1016\/j.canlet.2024.217100_bib10","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2024.217100_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/00220345211037220","article-title":"Dementia and the risk of periodontitis: a population-based cohort study","volume":"101","author":"Ma","year":"2022","journal-title":"J. Dent. Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.217100_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217100_bib13","article-title":"Tonsillectomy as a risk factor of periodontitis: a population-based cohort study","author":"Ma","year":"2021","journal-title":"J. Periodontol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217100_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13023-022-02223-x","article-title":"Age-dependent oral manifestations of neurofibromatosis type 1: a case-control study","volume":"17","author":"Thota","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"8","key":"10.1016\/j.canlet.2024.217100_bib15","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","article-title":"Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer","volume":"36","author":"Griffith","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.canlet.2024.217100_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer","volume":"3","author":"Stewart","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"10.1016\/j.canlet.2024.217100_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"16","key":"10.1016\/j.canlet.2024.217100_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2024.217100_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canlet.2024.217100_bib20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217100_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45596","article-title":"Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy","volume":"5","author":"Watson","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.canlet.2024.217100_bib22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","article-title":"Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer","volume":"19","author":"Jacob","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.canlet.2024.217100_bib23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.217100_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2022.01.017","article-title":"Severity of periodontitis and salivary interleukin-1\u03b2 are associated with psoriasis involvement","author":"Wu","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.canlet.2024.217100_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.752563","article-title":"Case report: in situ vaccination by autologous CD16+ dendritic cells and anti-PD-L 1 antibody synergized with radiotherapy to boost T cells-mediated antitumor efficacy in A psoriatic patient with cutaneous squamous cell carcinoma","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217100_bib26","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.canlet.2024.217100_bib27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2024.217100_bib28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/CIRCRESAHA.120.316770","article-title":"Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics","volume":"127","author":"Depuydt","year":"2020","journal-title":"Circ. Res."},{"issue":"Suppl 14","key":"10.1016\/j.canlet.2024.217100_bib29","first-page":"S70","article-title":"The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease","volume":"40","author":"Dietrich","year":"2013","journal-title":"J. Clin. Periodontol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524004956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524004956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:44:06Z","timestamp":1760816646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524004956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"alternative-id":["S0304383524004956"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217100","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217100"}}